ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2024 - FDA Approval Received Zydus Lifesciences has received final approval from the USFDA to manufacture Enzalutamide Capsules, 40 mg, which are indicated for treating metastatic castration-resistant prostate cancer, with annual sales of USD 869.4 million in the US..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd